Introduction
Anoctamin 1 (Ano1, TMEM16A) is a novel Ca 2þ -activated chloride channel (CaCC) with important physiological functions in epithelial cells and other cell types [1] [2] [3] [4] . It was also shown to be activated during cell swelling, probably secondary to an increase in intracellular Ca 2þ [5] . While some detected a role of Ca 2þ -dependent anoctamins, such as Ano1 or Ano6, to volume regulation, others did not [5, 6] . Upregulation of endogenous Ca 2þ -activated Cl 2 channels in proliferating cells has been observed recently, but the role of these channels for proliferation has remained unclear [7, 8] . Before Ano1 was identified as CaCC, it was already known as a protein that is coexpressed with the morphogen sonic hedgehog during embryonic development [9] . Ano1 was also known as DOG1, a protein strongly expressed in gastrointestinal stromal tumours and head and neck squamous cell carcinoma (HNSCC). Expression of DOG1 correlates with poor outcome in oesophageal squamous cell cancer [10] [11] [12] . Interstitial cells of Cajal (ICC) are another predominant site for Ano1 expression [13] [14] [15] . It has been reported that mice lacking Ano1 had fewer proliferating ICC [16] . Moreover, additional data suggested that Ano1 regulates proliferation at the G1/S transition of the cell cycle. Assuming such a pro-proliferative role, targeting of Ano1 has been proposed as a novel method for the treatment of malignant tumours [7, 17, 18] .
Ano1 is located on the 11q13 amplicon
The coding sequence of Ano1 is located within the 11q13 region, a chromosomal locus that is frequently amplified in a number of different human cancers, such as urinary bladder cancer, breast cancer and HNSCC [19] . The 11q13 amplicon & 2014 The Author(s) Published by the Royal Society. All rights reserved.
contains a stretch of proteins related to cell cycle, proliferation and apoptosis (cyclin D1, ORAOV1, FGF19, FGF4, TMEM16A, Fas-associated via death domain, PPFIA1, cortactin) [20] . The complex structure of this amplicon has mostly been studied in breast cancer, where multiple genes have been suggested as driver genes [21, 22] . These findings implied a link between Ano1 expression, cell-cycle regulation and proliferation, which has recently been demonstrated in HNSCC and other cancer cells [11, 16, [23] [24] [25] . Surprisingly, downregulation of Ano1 contributes to cerebrovascular remodelling by promoting basilar smooth muscle cell proliferation, which is through inhibition of expression of cyclin D1 and cyclin E [26] . We performed additional experiments and compared proliferation of two HNSCC (CAL33, BHY) and one colonic epithelial cell line (HT 29 ) using an online impedance-based xCELLigence proliferation assay system [27] (figure 1a). Proliferation was clearly higher in the HNSCC cell lines (cf. scale), which express much higher levels of Ano1, when compared with HT 29 cells (cf. western blot, figure 3a) [27] . In a previous study, we did not detect inhibition of proliferation of BHY cells by siRNA rstb.royalsocietypublishing.org Phil. Trans. R. Soc. B 369: 20130096 [27] . Using improved Stealth siRNA (cf. electronic supplementary material), these experiments were repeated. Proliferation was suppressed by siRNA-knockdown of Ano1 expression in HNSCC but not in HT 29 cells. These results suggest that very effective suppression of Ano1 expression is necessary to eliminate the pro-proliferative effects of Ano1, suggesting that low expression of Ano1 is sufficient to induce this effect. While siRNA had no effect in HT 29 cells, 1 mM staurosporine (figure 1a black arrow, dashed lines) inhibited proliferation and induced cell apoptosis in colonic carcinoma cells, as demonstrated in an earlier publication [28] . Thus, enhanced expression of Ano1 does not seem to enhance proliferation in every cell type [27, 29] . However, there is increasing consent that high levels of Ano1 lead to enhanced cell motility, distal metastasis and poor prognosis [23, 24, 27, 29] . Also in this study, cell attachment and migration was enhanced with increasing expression of Ano1 (BHY . CAL33 . HT 29 ) . It is further demonstrated that migration could be significantly inhibited by tannic acid, a blocker of Ano1 and other anoctamins ( figure 1c,d ). Moreover, migration was strongly dependent on the presence of serum in the migration chamber and was inhibited by the Ano1 inhibitor tannic acid (TA, figure 1e). Although proliferation, attachment and migration were positively correlated with expression of Ano1, this does not prove that Ano1 is directly responsible for the change of these properties.
Role of Ano1 for metastasis
How does Ano1 control the ability of tumour cells to migrate and form distal metastasis? The relationship between ion channel currents, cell volume regulation, migration and metastasis is well established [30] [31] [32] [33] . Previous findings indicate that Ano1 is activated during hypotonic cell swelling and contributes to regulatory volume decrease (RVD), which certainly requires a rise in intracellular Ca 2þ [5, 27, 34] . A rise in intra- Importantly, cell migration requires constant depolymerization and repolymerization of the actin cytoskeleton, which permanently changes cell-matrix adhesions [36, 37] . Our earlier findings suggested that Ano1 Cl 2 currents are controlled by the actin cytoskeleton [38] . This was supported by a subsequent report indicating that Ano1 associates with the signalling/scaffolding proteins ezrin, radixin, moesin and RhoA, which are known to connect plasma membrane proteins to the cytoskeleton [39] . Moreover, results from a two hybrid split ubiquitin screening suggested interaction of Ano1 with a number of proteins related to cell attachment and migration, such as zyxin, fibulin 1, S100A11, twinfilin and catenin (unpublished results from the Kunzelmann laboratory, K. Kunzelman 2012, figure 2 ). It was shown that members of the Rho GTPase family exert effects on cell shape and motility by regulating actin cytoskeleton; the activation of Rac1 organizes cortical actin cytoskeleton and promotes formation of lamellipodia at the leading edge, a hallmark of a motile cell, while the activation of RhoA at the rear influences acto-myosin complexes to allow retraction of the trailing end. Spatial and temporal regulation of the activity at each end create an unequal distribution of membranous, cytoskeletal and cytoplasmic contents to induce a highly polarized, motile shape that is suitable for movement and metastasis [32] . Thus, the presence of Ano1 at the plasma membrane, its ability to regulate cell shape and volume, and its connections to cytoplasmic/cytoskeletal elements is likely to contribute to cell movement and metastasis.
Regulation of expression of Ano1 by histone deacetylase and clinical implications
Recruitment of histone acetyltransferases and histone deacetylases (HDACs) is a key element in the dynamic regulation of genes controlling cellular proliferation and differentiation during normal development as well as carcinogenesis [40, 41] . A number of anti-cancer treatments are based on the inhibition of HDAC. HDAC inhibitors promote expression of p21 in breast cancer cells, which inhibits the action of cyclin D1. HDAC inhibitors may therefore also be useful for the treatment of those HNSCC that show overexpression of Ano1 and concomitant activation of cyclin D1 [23] . In fact, HDAC inhibitors have already entered preclinical evaluation [42, 43] . In recent experiments, we found that pronounced expression of Ano1 in the HNSCC cell line BHY was largely inhibited by treatment with the HDCA inhibitors valproic acid or butyric acid, along with inhibition of cell survival and Ano1-dependent whole cell currents ( figure 3a-f ) rstb.royalsocietypublishing.org Phil. Trans. R. Soc. B 369: 20130096 between Ano1 expression and proliferation. Corresponding to the data discussed in figure 1 , which did not identify a role Ano1 expression for proliferation of HT 29 colonic epithelial cells, expression levels for Ano1 were much lower and were not affected by HDCA inhibitors. As pointed out, expression levels for Ano1 are much higher in HNSCC compared with normal tissues (figure 3g). We also found a dose-dependent inhibition of proliferation of another HNSCC cell line, UM-SCC cancer cells, by a third type of HDAC-inhibitor, trichostatin (TSA) (figure 3h). UM-SCC cells contain amplification of the Ano1 gene locus similar to BHY cells. The results confirm that the inhibitory effect of HDAC inhibitors on Ano1 expression is independent of the HNSCC cell line used. While valproic acid and butyric acid are rather broad, non-selective inhibitors of HDAC, TSA selectively suppresses class I/II, suggesting that Ano1 expression is regulated by these HDACs. Although the mechanisms by which TSA promotes loss of cell survival/growth in these cells is incompletely understood, the present results support the use of HDAC inhibitors for the treatment of HNSCC, which may act in part through inhibition of Ano1 expression.
Ano1 and sonic hedgehog
Interesting links exist between Ano1 and the sonic hedgehog (Hh) signalling pathway. Hh is coexpressed with Ano1 in the zone of polarizing activity in mouse limb buds during E10.5 and E11.5 [44] . Hh signalling controls many aspects of development and also regulates cell growth and differentiation in adult tissues. It is activated in a number of human malignancies. Hh and Wnt signalling frequently act together in controlling cell growth and tissue morphogenesis. Hh is also active in 'embryonic cancers' such as basal cell carcinoma of the skin, stromal cancer [45, 46] and also during epithelial to mesenchymal transition. Hh expression has been shown to be upregulated in the neoplastic or inflammatory intestine when stem cells compensate for epithelial damage, while suppression rstb.royalsocietypublishing.org Phil. Trans. R. Soc. B 369: 20130096 of hedgehog signalling by cyclopamine has been shown to induce apoptosis [47, 48] . It will be interesting to learn more about the correlations between Hh signalling, Ano1 expression and cancer.
Ano1 required for terminal differentiation?
In cell types others than GIST, Ano1 has been reported to be inhibitory on cell proliferation and expression of Ano1 was related to cellular differentiation [26, 49] . These somewhat surprising results were supported by our own results indicating inhibition of cell proliferation by Ano1 in colonic epithelial cells (figure 1a). Interestingly, one study identified Ano1 by expression cloning in oocytes from axolotl, a salamander that does not undergo terminal differentiation and metamorphosis, and therefore maintains an amazing ability to regenerate limbs and other parts of the body [4] . Terminal differentiation is missing in these animals because of a complete lack of thyroid hormones. Maybe more than a coincidence, plasma thyronine levels were found to be abnormally low in patients with advanced colon carcinoma [50] . It might be worth examining whether expression of Ano1 is regulated by these hormones. We found evidence for regulation of Ano1 expression by the tumour suppressor adenomatosis polyposis coli (APC) in mouse colon. Ano1 is expressed in mouse ileum, proximal and particularly distal colon, but its expression is largely attenuated in APC min/þ mice. APC min/þ mice demonstrate reduced tumour suppressive activity by APC, resulting in upregulation of mTOR, thus leading to numerous large intestinal polyps and ultimately cancer (figure 4a,b) [51] . APC min/þ mice develop particularly large polyps in the distal colon, where we detected a pronounced decrease in Ano1 expression. Notably, the mTOR-inhibitor rapamycin increased Ano1 expression in both proximal and distal colon (figure 4d). This inverse correlation between low Ano1 levels and upregulation of mTOR [51] suggests that Ano1 may be inhibitory on proliferation of mouse intestinal epithelial cells, similar to HT 29 cells. Interestingly, a fast growing subclone of T 84 colonic epithelial cells (T 84 fast) is lacking expression of Ano1, when compared with the slowly growing parental cells (T 84 slow) [28] ( figure 5a,b) . Notably, treatment of fast growing T 84 cells with the mTOR-inhibitor rapamycin reduced proliferation and induced expression of Ano1 ( figure 5c,d ). These data support the concept that effects of Ano1 on cell survival are cell-type dependent [26, 29] .
Other anoctamins correlated to cancer
Apart from Ano1 and Ano2, much less information is available for other anoctamins. Although a deeper understanding is currently lacking, it should be mentioned that various anoctamins have a role during murine embryogenesis [9] . Ano7 (TMEM17G, NGEP) has been detected in prostate cancer [52, 53] . Studies indicate that the long version of NGEP is present on the plasma membrane of overexpressing LNCaP cells and is highly concentrated at cell-cell contact regions [53] . A splice form of Ano6 was identified that was associated with metastatic capability of mammary cancers in mouse and was related to poor prognosis of patients with breast cancer [54] . Notably, Ano6 has recently been associated with membrane phospholipid scrambling and cell shrinkage and therefore seems to be correlated to apoptosis rather than proliferation and cancer [55] [56] [57] [58] [59] . The distribution of lipids in the outer and inner leaflets of plasma membranes is asymmetrical: while phosphatidylcholine is mainly found in the outer leaflet, phosphatidylserine is present in the inner surface. During signalling events such as activation of platelets or cellular apoptosis, the distribution is rapidly altered leading to exposure of phosphatidylserine at the outer surface. A lipid transporter with phospholipid scrambling activity was proposed to be responsible for this process; however, a convincing candidate protein with such ability was not identified until recently. Surprisingly, a member of the TMEM16 family, TMEM16F (Ano6) was shown to contain phospholipid scrambling activity, when activated by a large increase in intracellular Ca 2þ [58] . Moreover, reconstitution experiments in Ano6-deficient thymocytes suggested that other anoctamins such as Ano3, Ano4, Ano7 and Ano9 retain the ability to function as calcium-dependent phospholipid scramblase [60] . These results came as a surprise, since Ano6 has been characterized as a Ca 2þ -activated Cl 2 channel. Moreover, Ca 2þ -activated Cl 2 currents were also observed after overexpression of Ano4, 7 and 9 [6, 55, 56, 61, 62] . However, Cl 2 channel and scramblase activity were shown to be independent [55] . Moreover, we demonstrated recently that Ano6 is activated during cell swelling and by pro-apoptotic stimuli and therefore contributes to both RVD as well as apoptotic volume decrease [5, 55, 56] . Notably, the amplicon 11q13 that contains the Ano1 gene, not only carries genes that control proliferation but also FADD, a gene associated with apoptosis. Thus, anoctamins can also be regarded as a novel family of regulators of cell proliferation and apoptosis, which may be of particular relevance during development, activation of immune cells such as lymphocytes, dendritic cells [63] and macrophages, and in particular types of cancer.
Conclusion
Functional analysis of Ano1 and the other members of the anoctamin family have just begun. These proteins were recognized initially as cancer-associated proteins and are now discussed in the context of ion conductance, volume regulation and phospholipid scrambling. Because ion movement, RVD, lipid scrambling and migration are related and are dysfunctional in cancer and metastasis, anoctamins have great potential as therapeutic drugs. Thus, it will be exciting to analyse how inhibitors of anoctamins affect cancer progression, metastasis and the prognosis particularly of patients with head and neck cancer.
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